Literature DB >> 20635173

Surgical margins and local control in resection of sacral chordomas.

Pietro Ruggieri1, Andrea Angelini, Giuseppe Ussia, Maurizio Montalti, Mario Mercuri.   

Abstract

BACKGROUND: The treatment of choice in sacral chordoma is surgical resection, although the risk of local recurrence and metastasis remains high. The quality of surgical margins obtained at initial surgery is the primary factor to improve survival reducing the risk of local recurrence, but proximal sacral resections are associated with substantial perioperative morbidity. QUESTIONS/PURPOSES: We considered survivorship related to local recurrence in terms of surgical margins, level of resection, and previous surgery.
METHODS: We retrospectively reviewed 56 patients with sacral chordomas treated with surgical resection. Thirty-seven were resected above S3 by a combined anterior and posterior approach and 19 at or below S3 by a posterior approach. Nine of these had had previous intralesional surgery elsewhere. The minimum followup was 3 years (mean, 9.5 years; range, 3-28 years).
RESULTS: Overall survival was 97% at 5 years, 71% at 10 years, and 47% at 15 years. Survivorship to local recurrence was 65% at 5 years and 52% at 10 years. Thirty percent of patients developed metastases. Wide margins were associated with increased survivorship to local recurrence. We found no differences in local recurrence between wide and wide-contaminated margins (that is, if the tumor or its pseudocapsule was exposed intraoperatively, but further tissue was removed to achieve wide margins). Previous intralesional surgery was associated with an increased local recurrence rate. We observed no differences in the recurrence rate in resections above S3 or at and below S3.
CONCLUSIONS: Surgical margins affect the risk of local recurrence. Previous intralesional surgery was associated with a higher rate of local recurrence. Intraoperative contamination did not affect the risk of local recurrence when wide margins were subsequently attained.

Entities:  

Mesh:

Year:  2010        PMID: 20635173      PMCID: PMC2947680          DOI: 10.1007/s11999-010-1472-8

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  56 in total

1.  Level-adjusted perioperative risk of sacral amputations.

Authors:  Clinton Devin; Paul Y Chong; Ginger E Holt; Irene Feurer; Adriana Gonzalez; Nipun Merchant; Herbert S Schwartz
Journal:  J Surg Oncol       Date:  2006-09-01       Impact factor: 3.454

2.  Risks of sacral amputations.

Authors:  Eugene R Mindell
Journal:  J Surg Oncol       Date:  2006-09-01       Impact factor: 3.454

3.  Neurourologic evaluation after resection of the sacrum.

Authors:  B Gunterberg; L Norlén; B Stener; T Sundin
Journal:  Invest Urol       Date:  1975-11

4.  Oncologic and functional outcome following sacrectomy for sacral chordoma.

Authors:  Christopher A Hulen; H Thomas Temple; William P Fox; Andrew A Sama; Barth A Green; Frank J Eismont
Journal:  J Bone Joint Surg Am       Date:  2006-07       Impact factor: 5.284

5.  Chordoma. Thirty-five-year study at Memorial Hospital.

Authors:  N L Higinbotham; R F Phillips; H W Farr; H O Hustu
Journal:  Cancer       Date:  1967-11       Impact factor: 6.860

Review 6.  Surgical treatment of primary sacral tumors: complications associated with sacrectomy.

Authors:  Mehmet Zileli; Cüneyt Hoscoskun; Priscilla Brastianos; Dündar Sabah
Journal:  Neurosurg Focus       Date:  2003-11-15       Impact factor: 4.047

7.  Carbon ion radiotherapy for unresectable sacral chordomas.

Authors:  Reiko Imai; Tadashi Kamada; Hiroshi Tsuji; Takeshi Yanagi; Masayuki Baba; Tadaaki Miyamoto; Shingo Kato; Susumu Kandatsu; Jun-etsu Mizoe; Hirohiko Tsujii; Shin-ichiro Tatezaki
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

8.  Sacral chordoma: can local recurrence after sacrectomy be predicted?

Authors:  S A Hanna; W J S Aston; T W R Briggs; S R Cannon; A Saifuddin
Journal:  Clin Orthop Relat Res       Date:  2008-06-27       Impact factor: 4.176

9.  New indications for computer-assisted surgery: tumor resection in the pelvis.

Authors:  Tobias Hüfner; Maurício Kfuri; Michael Galanski; Leonard Bastian; Martin Loss; Tim Pohlemann; Christian Krettek
Journal:  Clin Orthop Relat Res       Date:  2004-09       Impact factor: 4.176

Review 10.  Imaging of sacral tumours.

Authors:  S Gerber; L Ollivier; J Leclère; D Vanel; G Missenard; H Brisse; G de Pinieux; S Neuenschwander
Journal:  Skeletal Radiol       Date:  2007-11-23       Impact factor: 2.199

View more
  48 in total

1.  [Primary malignant bone tumors].

Authors:  R von Eisenhart-Rothe; A Toepfer; M Salzmann; J Schauwecker; H Gollwitzer; H Rechl
Journal:  Orthopade       Date:  2011-12       Impact factor: 1.087

2.  CORR Insights(®): Sacral Insufficiency Fractures are Common after High-dose Radiation for Sacral Chordomas Treated With or Without Surgery.

Authors:  Joshua C Patt
Journal:  Clin Orthop Relat Res       Date:  2015-10-30       Impact factor: 4.176

3.  CORR(®) Tumor Board: Sacral Insufficiency Fractures are Common After High-dose Radiation for Sacral Chordomas Treated With or Without Surgery.

Authors:  Megan E Anderson; Jim S Wu; Sara O Vargas
Journal:  Clin Orthop Relat Res       Date:  2015-12-07       Impact factor: 4.176

4.  What Are the Functional Outcomes After Total Sacrectomy Without Spinopelvic Reconstruction?

Authors:  Piya Kiatisevi; Chaiwat Piyaskulkaew; Sombat Kunakornsawat; Bhasanan Sukunthanak
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

5.  Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.

Authors:  Matthew T Houdek; Peter S Rose; Mario Hevesi; Joseph H Schwab; Anthony M Griffin; John H Healey; Ivy A Petersen; Thomas F DeLaney; Peter W Chung; Michael J Yaszemski; Jay S Wunder; Francis J Hornicek; Patrick J Boland; Franklin H Sim; Peter C Ferguson
Journal:  J Surg Oncol       Date:  2019-02-07       Impact factor: 3.454

6.  Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.

Authors:  M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

7.  Image-guided percutaneous lipiodol-pingyangmycin suspension injection therapy for sacral chordoma.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Renhua Wu; Yanhao Li
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

8.  "En bloc" resection of sacral chordomas by combined anterior and posterior surgical approach: a monocentric retrospective review about 29 cases.

Authors:  Arnaud Dubory; Gilles Missenard; Benoît Lambert; Charles Court
Journal:  Eur Spine J       Date:  2014-01-28       Impact factor: 3.134

9.  What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Authors:  Tao Ji; Wei Guo; Rongli Yang; Xiaodong Tang; Yifei Wang; Lin Huang
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

10.  Surgical workflow for fully navigated high sacral amputation in sacral chordoma.

Authors:  Johannes Goldberg; Simon Heinrich Bayerl; Christian Witzel; Felix Aigner; Christopher P Ames; Peter Vajkoczy
Journal:  Neurosurg Rev       Date:  2019-11-18       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.